Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Burkitt Lymphoma 14Lymphoma, Large B-Cell, Diffuse 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Wilms Tumor 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Lymphoma 3Plasmablastic Lymphoma 2Neoplasms 2Medulloblastoma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Ganglioneuroblastoma 2Down Syndrome 2Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdoid Tumor 1Osteosarcoma 1Neuroblastoma 1Multi-centric Castleman's Disease 1Malignant mesenchymal tumor 1

Interventions

Etoposide 3daratumumab 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2prednylidene 1pomalidomide 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Dexamethasone 1Cytarabine 1Carmustine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × Vincristine × 30 days × Clear all
NCT04139304 2026-06-01

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

AIDS Malignancy Consortium

Phase EARLY_PHASE1 Recruiting
15 enrolled
Lymphoid

Plasmablastic Lymphoma

NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡